Elanco Animal Health is worth buying even after its rally this year, according to JPMorgan. Analyst Chris Schott on Tuesday upgraded Elanco to overweight from neutral, saying the American pharmaceutical company for pets and livestock has several attractive products that are poised to do well. “We are upgrading ELAN shares to OW from N into an attractive innovation cycle,” Schott wrote. “The launch of Credelio Quattro is progressing well ahead of expectations with the product gaining traction in parts of the market and starting to become a meaningful contributor to revenues. Experior (along with the broader farm animal portfolio) is also performing well which is often overlooked by the Street.” “Between Credelio Quattro, Experior and other recent and upcoming launches (such as Zenrelia exUS, Bovaer and IL-31) we see revenue growth accelerating at ELAN in the coming years (which we expect will flow through the P & L supporting margins and EPS),” he continued. Credelio Quattro is a chewable tablet for dogs that provides broad parasite protection. Experior is a feed supplement for beef cattle that reduces ammonia gas emissions. ELAN 1D mountain Elanco Animal Health, 1 day performance Elanco shares have outperformed in 2025, surging 70% in a year in which the S & P 500 has advanced more than 14%. It has bested the performance of many of the mega-cap tech companies. Yet, the analyst said Elanco remains attractive even with that rally. His $24 price target, hiked from $18 previously, represents more than 16% upside for the animal health stock from Monday’s closing price. Shares were higher by more than 3% in the Tuesday premarket. “While ELAN shares have had a strong run this year we see a favorable setup from here as the company continues to execute (and with estimates likely moving higher over time),” Schott wrote. ( Learn the best 2026 strategies from inside the NYSE with Josh Brown and others at CNBC PRO Live. Tickets and info here . )
